Amphiregulin as a Mediator of Radiation-Induced Systemic Effects in Metastatic Cancer: Balancing Local Control with...

Area of Science:

• Oncology
• Immunology
• Radiotherapy

Background:

• Metastasis-directed therapies like SBRT are used for limited metastatic cancer.
• SBRT may cause unintended systemic effects, altering the tumor-immune landscape.
• Amphiregulin (AREG), an EGFR ligand, is implicated in radiation-induced metastatic changes.

Purpose of the Study:

• To investigate the role of AREG in SBRT-induced systemic effects.
• To explore AREG as a mediator of immune escape after radiotherapy.
• To evaluate therapeutic strategies targeting AREG and its downstream pathways.

Main Methods:

• Analysis of clinical cohorts and murine models.
• Assessment of AREG upregulation following SBRT.
• Investigating AREG's effects on myeloid cells and macrophage differentiation.
• Evaluating CD47 expression on tumor cells.
• Preclinical testing of AREG blockade combined with anti-CD47 antibodies and radiotherapy.

Main Results:

• SBRT caused significant AREG upregulation in clinical and preclinical models.
• AREG promoted monocyte differentiation into immunosuppressive macrophages, facilitating immune escape.
• Elevated AREG correlated with increased metastatic progression and poorer survival.
• AREG signaling increased CD47 expression on tumor cells, hindering macrophage clearance.
• Combined AREG blockade, anti-CD47 antibodies, and radiotherapy suppressed local and distant disease.

Conclusions:

• AREG is a key mediator of SBRT-induced immune suppression and metastatic progression.
• Targeting AREG and CD47 offers a promising therapeutic strategy to enhance radiotherapy efficacy.
• Understanding SBRT's dual effects—local control and immune modulation—is crucial for optimizing cancer treatment.